Investors Buy Large Volume of Put Options on Zevra Therapeutics (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) was the recipient of unusually large options trading activity on Thursday. Investors bought 6,717 put options on the stock. This represents an increase of 111% compared to the average volume of 3,177 put options.

Zevra Therapeutics Trading Down 1.6%

Shares of ZVRA stock traded down $0.18 during trading hours on Thursday, hitting $11.14. The company’s stock had a trading volume of 40,782 shares, compared to its average volume of 1,271,976. The business has a fifty day moving average of $11.55 and a 200-day moving average of $11.28. The stock has a market cap of $661.54 million, a price-to-earnings ratio of 12.11 and a beta of 0.95. Zevra Therapeutics has a twelve month low of $8.01 and a twelve month high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.14. The business had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. On average, equities analysts expect that Zevra Therapeutics will post 0.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ZVRA has been the topic of a number of analyst reports. Cantor Fitzgerald lifted their price objective on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. Weiss Ratings restated a “hold (c)” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 19th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. HC Wainwright reiterated a “buy” rating and set a $26.00 price target on shares of Zevra Therapeutics in a research note on Thursday, August 20th. Finally, UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a research report on Thursday, August 20th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.14.

Insiders Place Their Bets

In other news, Director Corey Watton sold 12,300 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $11.25, for a total value of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares of the company’s stock, valued at approximately $20,250. This represents a 87.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds have recently modified their holdings of the stock. Tidal Investments LLC acquired a new position in Zevra Therapeutics during the 2nd quarter worth approximately $150,000. WINTON GROUP Ltd grew its position in Zevra Therapeutics by 49.0% in the second quarter. WINTON GROUP Ltd now owns 24,335 shares of the company’s stock valued at $349,000 after acquiring an additional 8,001 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Zevra Therapeutics in the second quarter valued at $28,000. Wellington Management Group LLP boosted its position in Zevra Therapeutics by 5.2% in the 2nd quarter. Wellington Management Group LLP now owns 164,538 shares of the company’s stock valued at $2,359,000 after buying an additional 8,121 shares during the last quarter. Finally, Globeflex Capital L P purchased a new stake in Zevra Therapeutics during the 2nd quarter worth approximately $2,752,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a rare-disease biopharmaceutical company focused on developing and commercializing treatments for conditions with significant unmet medical needs. The company combines data science, patient-focused drug development and traditional pharmaceutical research to advance therapies for rare metabolic and neurological disorders.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children at least 2 years old, in combination with miglustat.